Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 3164

1.

Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice.

Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, Mori T, Cao C, Arendash GW.

Neuroscience. 2009 Sep 29;163(1):55-72. doi: 10.1016/j.neuroscience.2009.05.071. Epub 2009 Jun 14.

PMID:
19500657
2.

Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.

Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S.

Brain. 2009 Apr;132(Pt 4):1078-92. doi: 10.1093/brain/awn331. Epub 2009 Jan 17.

PMID:
19151372
3.

Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice.

Malm TM, Koistinaho M, Pärepalo M, Vatanen T, Ooka A, Karlsson S, Koistinaho J.

Neurobiol Dis. 2005 Feb;18(1):134-42.

PMID:
15649704
4.

Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice.

Seabrook TJ, Jiang L, Maier M, Lemere CA.

Glia. 2006 May;53(7):776-82.

PMID:
16534778
6.

Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease.

Richard KL, Filali M, Préfontaine P, Rivest S.

J Neurosci. 2008 May 28;28(22):5784-93. doi: 10.1523/JNEUROSCI.1146-08.2008.

7.

A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment.

Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M, Figueroa H, Yu WH, Arancio O, Duff K.

Neurobiol Dis. 2008 Jul;31(1):46-57. doi: 10.1016/j.nbd.2008.03.005. Epub 2008 Apr 7.

PMID:
18504134
8.

Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease.

Donovan MH, Yazdani U, Norris RD, Games D, German DC, Eisch AJ.

J Comp Neurol. 2006 Mar 1;495(1):70-83.

PMID:
16432899
9.

Microglial VEGF receptor response is an integral chemotactic component in Alzheimer's disease pathology.

Ryu JK, Cho T, Choi HB, Wang YT, McLarnon JG.

J Neurosci. 2009 Jan 7;29(1):3-13. doi: 10.1523/JNEUROSCI.2888-08.2009.

10.

CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease.

Imbimbo BP, Giardino L, Sivilia S, Giuliani A, Gusciglio M, Pietrini V, Del Giudice E, D'Arrigo A, Leon A, Villetti G, Calzà L.

J Alzheimers Dis. 2010;20(1):159-73. doi: 10.3233/JAD-2010-1366.

PMID:
20164581
11.

Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice.

Biscaro B, Lindvall O, Hock C, Ekdahl CT, Nitsch RM.

J Neurosci. 2009 Nov 11;29(45):14108-19. doi: 10.1523/JNEUROSCI.2055-09.2009.

12.

Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.

Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J.

Neuroscience. 2006 Nov 3;142(4):941-52. Epub 2006 Aug 28.

PMID:
16938404
13.

Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.

Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, Arendash GW.

J Pineal Res. 2009 Aug;47(1):82-96. doi: 10.1111/j.1600-079X.2009.00692.x. Epub 2009 Jun 17.

PMID:
19538338
14.

Noggin and BMP4 co-modulate adult hippocampal neurogenesis in the APP(swe)/PS1(DeltaE9) transgenic mouse model of Alzheimer's disease.

Tang J, Song M, Wang Y, Fan X, Xu H, Bai Y.

Biochem Biophys Res Commun. 2009 Jul 31;385(3):341-5. doi: 10.1016/j.bbrc.2009.05.067. Epub 2009 May 20.

PMID:
19463786
15.

Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model.

Reilly JF, Games D, Rydel RE, Freedman S, Schenk D, Young WG, Morrison JH, Bloom FE.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4837-42.

16.

Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism.

Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD.

Exp Neurol. 2001 Sep;171(1):29-45.

PMID:
11520119
17.

Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease.

Simard AR, Soulet D, Gowing G, Julien JP, Rivest S.

Neuron. 2006 Feb 16;49(4):489-502.

18.

Amyloid beta protein deposition and neuron loss in osteopetrotic (op/op) mice.

Kaku M, Tsutsui K, Motokawa M, Kawata T, Fujita T, Kohno S, Tohma Y, Ohtani J, Tenjoh K, Tanne K.

Brain Res Brain Res Protoc. 2003 Oct;12(2):104-8.

PMID:
14613812
19.
20.

Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology.

Hao W, Liu Y, Liu S, Walter S, Grimm MO, Kiliaan AJ, Penke B, Hartmann T, Rübe CE, Menger MD, Fassbender K.

Brain. 2011 Jan;134(Pt 1):278-92. doi: 10.1093/brain/awq325. Epub 2010 Nov 28.

PMID:
21115468

Supplemental Content

Support Center